Healthcare


 Why Healthcare Stocks Like Pro Medicus (ASX:PME) And CSL (ASX:CSL) Are Bouncing Back

Why Healthcare Stocks Like Pro Medicus (ASX:PME) And CSL (ASX:CSL) Are Bouncing Back

July 01, 2026 01:40 PM AEST| By Sam

Healthcare stocks rebounded strongly as Pro Medicus, CSL, Ramsay Health Care and Sonic Healthcare recovered, while Echo IQ, Biome Australia and Memphasys delivered notable corporate developments supporting sector momentum.

 Amcor (ASX:AMC) or Sonic Healthcare (ASX:SHL): Which ASX Share Looks More Compelling Right Now?

Amcor (ASX:AMC) or Sonic Healthcare (ASX:SHL): Which ASX Share Looks More Compelling Right Now?

July 01, 2026 11:22 AM AEST| By Sam

Amcor and Sonic Healthcare continue attracting attention through global operations, diversified revenue streams and resilient business models as packaging innovation and healthcare demand remain long-term structural growth themes.

 Kalina Power (ASX:KPO), Mitchell Services (ASX:MSV) and Sigma Healthcare (ASX:SIG): Why These ASX Stocks Are Gaining Attention

Kalina Power (ASX:KPO), Mitchell Services (ASX:MSV) and Sigma Healthcare (ASX:SIG): Why These ASX Stocks Are Gaining Attention

July 01, 2026 11:03 AM AEST| By Sam

Kalina Power, Mitchell Services and Sigma Healthcare remain under market attention through improving financial resilience, disciplined balance sheet management and continued operational progress across Australia's energy, mining and healthcare sector...

Sponsored
https://kalkineauuknzusca.blob.core.windows.net/kalkineallsubdata/au/gallery/xlarge/Goldminmn_07_01_2026_03_14_53_301342.jpg

Siren Gold (ASX: SNG) Rises 20% as High-Grade Gold Exploration Continues to Build Momentum

July 01, 2026 03:12 AM AEST| By Aditi Sarkar

• Siren Gold shares climbed 20.00% to AUD 0.054 during Wednesday's trading session.

 Why Is 4DMedical (ASX:4DX) Leading the ASX 200 FY26 Winners?

Why Is 4DMedical (ASX:4DX) Leading the ASX 200 FY26 Winners?

July 01, 2026 09:48 AM AEST| By Sam

Australia's latest financial year highlighted contrasting sector performance, with mining supporting the broader market while 4DMedical gained attention through regulatory progress, commercial expansion and healthcare technology innovation.

 CSL (ASX:CSL) Shares Back in Focus as Healthcare Giant Rebuilds

CSL (ASX:CSL) Shares Back in Focus as Healthcare Giant Rebuilds

June 30, 2026 10:47 PM AEST| By Sam

CSL is regaining attention as its resilient plasma franchise, steady underlying earnings and ongoing restructuring reinforce the company's position as one of Australia's leading healthcare businesses despite near-term operational challenges.

 Why Are CSL (ASX:CSL) Shares Rallying as Healthcare Roars Back?

Why Are CSL (ASX:CSL) Shares Rallying as Healthcare Roars Back?

June 30, 2026 10:20 PM AEST| By Vivek Singh

CSL led Australia's healthcare rebound as capital shifted away from resource companies into defensive growth businesses, placing renewed attention on restructuring progress and the sector's improving market sentiment.

Sponsored
https://kalkineauuknzusca.blob.core.windows.net/kalkineallsubdata/au/gallery/xlarge/Biopharamanmn_07_01_2026_03_13_56_428618.jpg

Clinical Trial Progress Sparks Fresh Interest in Imugene (ASX: IMU) Shares

July 01, 2026 03:11 AM AEST| By Aditi Sarkar

• Imugene shares surged 21.74% to AUD 0.14 during Wednesday's trading session.

 Why Pro Medicus (ASX:PME) Is Back in Focus After a Landmark US Deal

Why Pro Medicus (ASX:PME) Is Back in Focus After a Landmark US Deal

June 30, 2026 10:19 PM AEST| By Vivek Singh

Pro Medicus strengthened its position in healthcare technology after expanding a major US contract, reinforcing the success of its Visage Seven platform and highlighting continued momentum across large American healthcare networks.

 Why Is Pro Medicus (ASX:PME) Testing Healthcare Stocks?

Why Is Pro Medicus (ASX:PME) Testing Healthcare Stocks?

June 30, 2026 03:31 PM AEST| By Sam

ASX healthcare stocks are facing a clinical validation test as regulatory progress, specialist technology and rare-disease updates place execution quality back in focus.

 Why Is CSL (ASX:CSL) Central to Healthcare Rebound?

Why Is CSL (ASX:CSL) Central to Healthcare Rebound?

June 30, 2026 03:31 PM AEST| By Sam

ASX healthcare stocks are being tested through quality rebound, with earnings confidence, clinical credibility and margin discipline shaping the latest market screen.

Sponsored
https://kalkineauuknzusca.blob.core.windows.net/kalkineallsubdata/au/gallery/xlarge/shutterstock_2233875957_06_30_2026_13_24_43_159015.jpg

Is Megaport (ASX:MP1) Showing Investor Interest Despite Lower Volume?

June 30, 2026 01:16 PM AEST| By Sonal Goyal

• Shares rise 6.357% to 21.580 with strong upward session movement.

 Why Is Pro Medicus (ASX:PME) Driving the Diagnostics Shift in ASX Healthcare Stocks?

Why Is Pro Medicus (ASX:PME) Driving the Diagnostics Shift in ASX Healthcare Stocks?

June 30, 2026 03:31 PM AEST| By Sam

Australia's healthcare sector is increasingly defined by diagnostics, medical imaging and workflow technology, with leading healthcare companies demonstrating how innovation and commercial execution continue reshaping industry attention.

 Epiminder (ASX:EPI): Cash Position Remains Under Market Spotlight

Epiminder (ASX:EPI): Cash Position Remains Under Market Spotlight

June 30, 2026 10:08 AM AEST| By Sam

Epiminder continues advancing its healthcare technology platform while maintaining financial flexibility, with cash management, product development and commercial execution remaining central to its long-term growth strategy.

 CSL (ASX:CSL): Are AI Imaging Deals Changing Healthcare Valuations?

CSL (ASX:CSL): Are AI Imaging Deals Changing Healthcare Valuations?

June 29, 2026 04:41 PM AEST| By Sam

ASX healthcare stocks are being assessed through AI imaging partnerships, commercial channels, clinical progress and defensive earnings as medical technology becomes a sharper valuation signal.

Sponsored
https://kalkineauuknzusca.blob.core.windows.net/kalkineallsubdata/au/gallery/xlarge/shutterstock_2316992511_06_30_2026_13_23_19_520341.jpg

Can Increased Volume Signal Changing Momentum for Neuren Pharmaceuticals (ASX:NEU) stock?

June 30, 2026 01:15 PM AEST| By Sonal Goyal

• Shares rise 6.927% to 17.750, with volume above average levels.

 Biotech Stocks: The Milestone Map Investors Are Reading Into July

Biotech Stocks: The Milestone Map Investors Are Reading Into July

June 29, 2026 04:40 PM AEST| By Sam

Australia's healthcare sector is focusing on biotechnology milestones, commercial execution, medical technology adoption and defensive earnings as investors assess operational progress before the new financial year.

 Why Is ResMed (ASX:RMD) Winning Back the ASX 200 Healthcare Story?

Why Is ResMed (ASX:RMD) Winning Back the ASX 200 Healthcare Story?

June 29, 2026 04:03 PM AEST| By Sam

ResMed's latest quarterly performance highlighted stronger revenue growth and improving profitability, helping refocus attention on operational execution and the long-term demand for sleep healthcare solutions.

 Why Is CSL (ASX:CSL) Facing Its Toughest Healthcare Test in Years?

Why Is CSL (ASX:CSL) Facing Its Toughest Healthcare Test in Years?

June 29, 2026 04:02 PM AEST| By Sam

CSL has returned to focus as Australia's healthcare sector experiences broad weakness driven by changing market sentiment, sector rotation and renewed attention on defensive industries.

Sponsored
https://kalkineauuknzusca.blob.core.windows.net/kalkineallsubdata/au/gallery/xlarge/shutterstock_2384457543_06_30_2026_13_23_28_879112.jpg

Is Electro Optic (ASX:EOS) Approaching Upper Range Resistance After Recent Gains?

June 30, 2026 01:15 PM AEST| By Sonal Goyal

• Shares rise 6.625% to 10.300 with active intraday trading.

 Why Is Cochlear (ASX:COH) Facing Its Biggest Challenge Yet?

Why Is Cochlear (ASX:COH) Facing Its Biggest Challenge Yet?

June 29, 2026 04:02 PM AEST| By Sam

Cochlear has reset earnings expectations following weaker procedure volumes and hospital constraints, while its long-term healthcare business continues to benefit from structural demand for hearing solutions.

 Neuren Pharmaceuticals (ASX:NEU) Draws Attention as Drug Pipeline Strengthens

Neuren Pharmaceuticals (ASX:NEU) Draws Attention as Drug Pipeline Strengthens

June 29, 2026 10:06 AM AEST| By Sam

Neuren Pharmaceuticals continues advancing its rare disease pipeline as clinical development, licensing partnerships and regulatory progress remain key long-term business drivers.

 Why Is Telix Pharmaceuticals (ASX:TLX) Standing Out This Year?

Why Is Telix Pharmaceuticals (ASX:TLX) Standing Out This Year?

June 28, 2026 07:19 PM AEST| By Sam

Telix Pharmaceuticals, Lindian Resources and GemLife Communities showcase Australia's diverse growth landscape through healthcare innovation, rare earth development and specialised residential community expansion.

Sponsored
https://kalkineauuknzusca.blob.core.windows.net/kalkineallsubdata/au/gallery/xlarge/shutterstock_2709396727_06_30_2026_13_24_31_086394.jpg

Is IperionX (ASX:IPX) Showing Recovery Signs Within Its 52-Week Range?

June 30, 2026 01:15 PM AEST| By Sonal Goyal

• Shares rise 5.974% to 4.080 with steady intraday price movement.

 Why Is 4DMedical (ASX:4DX) Back in the Healthcare Spotlight?

Why Is 4DMedical (ASX:4DX) Back in the Healthcare Spotlight?

June 28, 2026 04:03 PM AEST| By Sam

4DMedical continues advancing its respiratory imaging technology through commercial expansion, healthcare innovation and growing clinical adoption across Australia and the United States.

 Why ResMed (ASX:RMD) Is Rebuilding Confidence on the ASX 200?

Why ResMed (ASX:RMD) Is Rebuilding Confidence on the ASX 200?

June 26, 2026 07:57 PM AEST| By Sam

ResMed continues demonstrating resilient healthcare demand through respiratory devices, digital health platforms and recurring revenue as market attention returns to its operating fundamentals.

AU_advertise

Advertise your brand on Kalkine Media

Recent Articles






Investing Tips

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.